Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of Isunakinra (EBI-005) in Patients with Allergic Conjunctivitis

Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of Isunakinra (EBI-005) in Patients with Allergic Conjunctivitis

October 15, 2015

-Eleven Granted Isunakinra as the International Nonproprietary Name for EBI-005-

Christopher A. Viehbacher Joins Pronutria Biosciences’ Board of Directors

Christopher A. Viehbacher Joins Pronutria Biosciences’ Board of Directors

October 15, 2015

Gurnet Point Capital Invests in Pronutria’s Series C Financing

BIND Therapeutics Expands Board of Directors with Appointment of Dr. Arthur Tzianabos

BIND Therapeutics Expands Board of Directors with Appointment of Dr. Arthur Tzianabos

October 14, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today announced the appointment of Arthur Tzianabos, Ph.D., president and chief scientific officer of OvaScience, Inc., to the Company's board of directors.

Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study

Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study

October 5, 2015

– Study Achieved its Primary Endpoint of Reduction in Viral Shedding; Treatment with VIS410 Resulted in a 92% Reduction of Virus vs. Placebo –

– Study Results Support Further Development of VIS410 in Hospitalized Patients with Influenza A –

Visterra Awarded Contract Valued at up to $204.5 Million to Advance the Development of VIS410, its Novel Monoclonal Antibody for the Treatment of Influenza A, by the Biomedical Advanced Research and Development Authority (BARDA)

Visterra Awarded Contract Valued at up to $204.5 Million to Advance the Development of VIS410, its Novel Monoclonal Antibody for the Treatment of Influenza A, by the Biomedical Advanced Research and Development Authority (BARDA)

October 5, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra, Inc., a clinical-stage biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics for infectious diseases, today announced that the Biomedical Advanced Research and Development Authority (BARDA) of the U.S.

Acceleron Presents Preclinical Data for ACE-083 and ACE-2494 at the 20th International Annual Congress of the World Muscle Society

Acceleron Presents Preclinical Data for ACE-083 and ACE-2494 at the 20th International Annual Congress of the World Muscle Society

October 1, 2015

-- First presentation of data for new systemic muscle agent, ACE-2494, demonstrates substantial increases in muscle mass --

Joule Achieves U.S. EPA Registration for CO2-Recycled Ethanol

Joule Achieves U.S. EPA Registration for CO2-Recycled Ethanol

September 30, 2015

Bedford, Mass Joule, the pioneer of liquid fuels from recycled CO2, today announced that its fuel grade Sunflow®-E ethanol has been registered by the U.S. Environmental Protection Agency (EPA) for commercial use in E10 and E15 gasoline blends.

FierceBiotech Names Syros Pharmaceuticals as One of Its “Fierce 15” Biotech Companies of 2015

FierceBiotech Names Syros Pharmaceuticals as One of Its “Fierce 15” Biotech Companies of 2015

September 30, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, the industry pioneer in gene control medicines, today announced that it has been named by FierceBiotech as one of 2015’s Fierce 15 biotechnology companies. The award designates Syros as one of the most promising private companies in the biotech industry.

WBCSD brings together over 200 business leaders to turn ambitious low-carbon targets into action for significant emission reductions

WBCSD brings together over 200 business leaders to turn ambitious low-carbon targets into action for significant emission reductions

September 25, 2015

Over 200 representatives from forward-thinking businesses around the globe are coming together in New York City during Climate Week, where action plans under the Low Carbon Technology Partnerships initiative (LCTPi) will be finalized for presentation at COP21 in Paris this December. The plans will deliver a significant contribution from the business sector to reduce emissions and ensure that the rise in global temperatures remains under the 2°C ceiling.

BIND Therapeutics Announces Pfizer Inc. Exercises Option to Advance Nanoparticle-Based Kinase Inhibitor for Treatment of Solid Tumors

BIND Therapeutics Announces Pfizer Inc. Exercises Option to Advance Nanoparticle-Based Kinase Inhibitor for Treatment of Solid Tumors

September 24, 2015

-- BIND earns $2.5 million option fee for first compound in global collaboration to pursue development and commercialization of novel Accurins --